Predicting 2-Year survival for radiation regimens in advanced non-small cell lung cancer

Clinical Oncology

Volumn 25, Issue 12, 2013, Pages 697-705

  Sharieff, W ^a,b,c,d   Okawara, G ^a,b   Tsakiridis, T ^a,b   Wright, J ^a,b  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Cape Breton Regional Hospital   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Biological equivalent dose; Dose response study; Non small cell lung cancer; Predictive modelling; Radiation therapy

Indexed keywords

ADVANCED CANCER; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; HUMAN; LUNG NON SMALL CELL CANCER; PREDICTIVE VALIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; VALIDATION STUDY;

BIOLOGICAL EQUIVALENT DOSE; DOSE-RESPONSE STUDY; NON-SMALL CELL LUNG CANCER; PREDICTIVE MODELLING; RADIATION THERAPY;

CARCINOMA, NON-SMALL-CELL LUNG; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MODELS, BIOLOGICAL; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84887022312     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.07.011     Document Type: Article

References (67)

1. Cancer facts and figures 2006, American Cancer Society, American Cancer Society, Atlanta.
2. Regaud C., Ferroux R. Discordance des effets de rayons X, d'une part dans le testicule, par le fractionnement de la dose. CR Soc Biol 1927, 97:431.
3. Puck T.T., Marcus P.I. Action of x-rays on mammalian cells. JExp Med 1956, 103(5):653-666.
4. Lea D.E.A. Actions of radiations on living cells 1956, Cambridge University Press, Cambridge. 2nd ed.
5. Fowler J. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989, 62(740):679-694.
6. Hall E. Radiobiology for the radiologist 2000, Lippincott Williams and Wilkins, Philadelphia, PA. 5th ed.
7. Okawara G., Mackay J.A., Evans W.K., Ung Y.C. Management of unresected stage III non-small cell lung cancer: a systematic review. JThorac Oncol 2006, 1(4):377-393.
8. Eddy D.M., Schlessinger L. Validation of the Archimedes diabetes model. Diabetes Care 2003, 26(11):3102-3110.
9. Atagi S., Kawahara M., Tamura T., et al. Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol 2005, 35(4):195-201.
10. Abratt R.P., Shepherd L.J., Salton D.G. Palliative radiation for stage 3 non-small cell lung cancer - a prospective study of two moderately high dose regimens. Lung Cancer 1995, 13(2):137-143.
11. Cakir S., Egehan I. Arandomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer 2004, 43(3):309-316.
12. Van Houtte P., Klastersky J., Renaud A., et al. Induction chemotherapy with cisplatin, etoposide and vindesine before radiation therapy for nonsmall-cell lung cancer. A randomized study. Antibiot Chemother 1988, 41:131-137.
13. Wolf M., Hans K., Becker H., et al. Radiotherapy alone versus chemotherapy with ifosfamide/vindesine followed by radiotherapy in unresectable locally advanced non-small cell lung cancer. Semin Oncol 1994, 21(3):S442-S447.
14. Clamon G., Herndon J., Cooper R., Chang A.Y., Rosenman J., Green M.R. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. JClin Oncol 1999, 17(1):4-11.
15. Routh A., Hickman B.T., Khansur T. Report of a prospective trial - split course versus conventional radiotherapy in the treatment of non-small cell lung cancer. Radiat Med 1995, 13(3):115-119.
16. Wils J., Utama I., Smeets J. Chemotherapy consisting of epirubicin, cisplatin, and etoposide followed by irradiation in stage III non-small cell lung cancer and chemotherapy alone in stage IV non-small cell lung cancer. Oncology 1988, 45(6):413-416.
17. Perez C.A., Stanley K., Grundy G., et al. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung: report by the Radiation Therapy Oncology Group. Cancer 1982, 50(6):1091-1099.
18. Teo P., Tai T.H., Choy D., Tsui K.H. Arandomized study on palliative radiation therapy for inoperable non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1988, 14(5):867-871.
19. Cox J.D., Azarnia N., Byhardt R.W., Shin K.H., Emami B., Pajak T.F. Arandomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0Gy to 79.2Gy: possible survival benefit with greater than or equal to 69.6Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. JClin Oncol 1990, 8(9):1543-1555.
20. Bleehen N.M., Girling D.J., Fayers P.M., Aber V.R., Stephens R.J. Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer 1991, 63(2):265-270.
21. Bleehen N.M., Girling D.J., Stephens R.J. AMedical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. Br J Cancer 1992, 65(6):934-941.
22. Macbeth F.R., Bolger J.J., Hopwood P., et al. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) 1996, 8(3):167-175.
23. Rees G.J., Devrell C.E., Barley V.L., Newman H.F. Palliative radiotherapy for lung cancer: two versus five fractions. Clin Oncol (R Coll Radiol) 1997, 9(2):90-95.
24. Bezjak A., Dixon P., Brundage M., et al. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys 2002, 54(3):719-728.
25. Sundstrøm S., Bremnes R., Aasebø U., et al. Hypofractionated palliative radiotherapy (17Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. JClin Oncol 2004, 22(5):801-810.
26. Kramer G.W., Wanders S.L., Noordijk E.M., et al. Results of the Dutch National study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer. JClin Oncol 2005, 23(13):2962-2970.
27. Erridge S.C., Gaze M.N., Price A., et al. Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules. Clin Oncol (R Coll Radiol) 2005, 17(1):61-67.
28. Soresi E., Clerici M., Grilli R., et al. Arandomized clinical trial comparing radiation therapy v radiation therapy plus cis-dichlorodiammine platinum (II) in the treatment of locally advanced non-small cell lung cancer. Semin Oncol 1988, 15(6 Suppl. 7):20-25.
29. Mattson K., Holsti L.R., Holsti P., et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 1988, 24(3):477-482.
30. Johnson D.H., Einhorn L.H., Bartolucci A., et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 1990, 113(1):33-38.
31. Le Chevalier T., Arriagada R., Quoix E., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. JNatl Cancer Inst 1991, 83(6):417-423.
32. Morton R.F., Jett J.R., McGinnis W.L., et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med 1991, 115(9):681-686.
33. Schaake-Koning C., Maat B., van Houtte P., et al. Radiotherapy combined with low-dose cis-diammine dichloroplatinum (II) (CDDP) in inoperable nonmetastatic non-small cell lung cancer (NSCLC): a randomized three arm phase II study of the EORTC Lung Cancer and Radiotherapy Cooperative Groups. Int J Radiat Oncol Biol Phys 1990, 19(4):967-972.
34. Trovó M.G., Minatel E., Franchin G., et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992, 24(1):11-15.
35. Blanke C., Ansari R., Mantravadi R., et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. JClin Oncol 1995, 13(6):1425-1429.
36. Jeremic B., Shibamoto Y., Acimovic L., Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. JClin Oncol 1995, 13(2):452-458.
37. Saunders M., Dische S., Barrett A., Harvey A., Gibson D., Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997, 350(9072):161-165.
38. Jeremic B., Shibamoto Y., Acimovic L., Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. JClin Oncol 1996, 14(4):1065-1070.
39. Dillman R.O., Seagren S.L., Propert K.J., et al. Arandomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. NEngl J Med 1990, 323(14):940-945.
40. Ball D., Smith J., Bishop J., et al. Aphase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancer. Br J Cancer 1997, 75(5):690-697.
41. Bonner J.A., McGinnis W.L., Stella P.J., et al. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study. Cancer 1998, 82(6):1037-1048.
42. Ball D., Bishop J., Smith J., et al. Arandomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol 1999, 52(2):129-136.
43. Cullen M.H., Billingham L.J., Woodroffe C.M., et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. JClin Oncol 1999, 17(10):3188-3194.
44. Sause W., Kolesar P., Taylor S.I.V., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000, 117(2):358-364.
45. Nestle U., Nieder C., Walter K., et al. Apalliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60Gy: results of a randomized equivalence study. Int J Radiat Oncol Biol Phys 2000, 48(1):95-103.
46. Kim T.Y., Yang S.H., Lee S.H., et al. Aphase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. Am J Clin Oncol 2002, 25(3):238-243.
47. Groen H.J., van der Leest A.H., Fokkema E., et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol 2004, 15(3):427-432.
48. Sharma S., Sharma R., Bhowmik K.T. Sequential chemoradiotherapy versus radiotherapy in the management of locally advanced non-small-cell lung cancer. Adv Ther 2003, 20(1):14-19.
49. Bradley J, Paulus R, Komaki R, etal. A randomized phase III comparison of standard-dose (60Gy) versus high-dose (74Gy) conformal chemoradiotherapy±cetuximab for stage IIIa/IIIb non-small cell lung cancer: preliminary findings on radiation dose in RTOG 0617 (late-breaking abstract 2). Presented at the 53rd Annual Meeting of the American Society of Radiation Oncology, October 2-6, 2011, Miami, FL.
50. Cox J.D. Are the results of RTOG 0617 mysterious?. Int J Radiat Oncol Biol Phys 2012, 82(3):1042-1044.
51. Overgaard J., Mohanti B.K., Begum N., et al. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. Lancet Oncol 2010, 11(6):553-560.
52. Neary G.J. Chromosome aberrations and the theory of RBE. 1. General considerations. Int J Radiat Biol 1965, 9(5):477-502.
53. Das S.K., Zhou S., Zhang J., Yin F.F., Dewhirst M.W., Marks L.B. Predicting lung radiotherapy-induced pneumonitis using a model combining parametric Lyman probit with nonparametric decision trees. Int J Radiat Oncol Biol Phys 2007, 68(4):1212-1221.
54. Chen S., Zhou S., Zhang J., Yin F.F., Marks L.B., Das S.K. Aneural network model to predict lung radiation-induced pneumonitis. Med Phys 2007, 34(9):3420-3427.
55. Das S.K., Chen S., Deasy J.O., Zhou S., Yin F.F., Marks L.B. Combining multiple models to generate consensus: application to radiation-induced pneumonitis prediction. Med Phys 2008, 35(11):5098-5109.
56. Chen S., Zhou S., Yin F.F., Marks L.B., Das S.K. Using patient data similarities to predict radiation pneumonitis via a self-organizing map. Phys Med Biol 2008, 53(1):203-216.
57. Robertson J.M., Söhn M., Yan D. Predicting grade 3 acute diarrhea during radiation therapy for rectal cancer using a cutoff-dose logistic regression normal tissue complication probability model. Int J Radiat Oncol Biol Phys 2010, 77(1):66-72.
58. Martel M.K., Ten Haken R.K., Hazuka M.B., et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 1999, 24(1):31-37.
59. Kalpathy-Cramer J., Hersh W., Kim J.S., Thomas C.R., Wang S.J. Survival prediction models for estimating the benefit of post-operative radiation therapy for gallbladder cancer and lung cancer. AMIA Annu Symp Proc 2008, 348-352.
60. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998, 352(9124):257-263. PORT Meta-analysis Trialists Group.
61. Chow E., Abdolell M., Panzarella T., et al. Predictive model for survival in patients with advanced cancer. JClin Oncol 2008, 26(36):5863-5869.
62. Chow E., Abdolell M., Panzarella T., et al. Validation of a predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. Int J Radiat Oncol Biol Phys 2009, 73(1):280-287.
63. Singer J.M., Price P., Dale R.G. Radiobiological prediction of normal tissue toxicities and tumour response in the radiotherapy of advanced non-small-cell lung cancer. Br J Cancer 1998, 78(12):1629-1633.
64. Barendsen G.W. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982, 8(11):1981-1997.
65. Brenner D.J., Hlatky L.R., Hahnfeldt P.J., Huang Y., Sachs R.K. The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships. Radiat Res 1998, 150:83-91.
66. Eddy D.M., Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003, 26(11):3093-3101.
67. Kahn R. Dealing with complexity in clinical diabetes: the value of Archimedes. Diabetes Care 2003, 26(11):3168-3171.